TTRA Information Session – Funding call for Devices addressing cardiovascular disease and complications of diabetes

Join our webinar, TTRA Information Session – Funding call for Devices addressing cardiovascular disease and complications of diabetes, and find out more about the program and the application process.

MTPConnect’s TTRA Drugs and Devices program aims to accelerate the development and commercialisation of promising drugs and medical devices into products that can reduce the burden of cardiovascular disease and complications of diabetes for patients, carers, families, and community. In 2025, MTPConnect awarded funding to the first TTRA Drugs & Device cohort.

MTPConnect is now calling for Expressions of Interest (EOI) for TTRA Devices Round 2, to fund eligible Australian start-ups, spin-outs and SMEs to develop innovative preventative, diagnostic, therapeutic and/or disease management devices for cardiovascular disease and the complications of diabetes (type 1 and type 2).

The funding will be delivered using MTPConnect’s purpose-built Accelerator model and can provide up to $1 million for up to 24 months (project must conclude by 30 September 2028).

Applicants will be required to provide a cash co-contribution relative to the value of the TTRA funding request to be eligible. Guidelines & application information can be found on MTPConnect’s TTRA webpage. Submissions close at 16:00 AEDT on Monday 30 March 2026.

Join our webinar to find out more about the program and the application process from MTPConnect’s TTRA Team:

• Lauren Kelly
• Dr Dharmica Mistry
• Dr Andionne Parlade

AUDIENCE: Diabetes and cardiovascular disease innovators, clinicians, SMEs, start-ups, spin-outs, research institutes, universities, industry, medical devices, therapeutics